Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE723 in advanced hepatocellular carcinoma
NCT07861425Phase 1Not yet recruiting
- Sponsor
- Acepodia
- Start
- Nov 2026
- Primary completion
- May 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ACE723 in hepatocellular carcinoma (HCC), sponsored by Acepodia. Primary endpoints: Safety and Tolerability at 12 months, Maximum Tolerated Dose at 12 months and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ACE723
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07861425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07861425.